RxDoctor Payments Data

Hashem Kalbouneh, MD

Hospitalist · Waterbury, CTNPI 1679133425

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AstraZeneca at 59.7% of the total. Reporting peaked in 2024 at $317 and has fallen 87.9% since, to $38 in 2025.

$645in general payments, 2019–2025

Across 19 payments — averaging $33.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$385
  • Pfizer$110
  • Johnson & Johnson$62
  • Novartis$48
  • Abbott$21
  • Mylan Specialty L.p.$19

What the payments were for

  • Food & beverage$645100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$385
Pfizer5$110
Johnson & Johnson3$62
Novartis2$48
Abbott1$21
Mylan Specialty L.p.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$645 in reported general payments places this provider in the 85th percentile of 349 hospitalist providers in Connecticut.

See all hospitalist providers in Connecticut

Medicare billing

Part B allowed, 2024
$77,412
Medicare patients
256
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor22$10,702
EliquisApixaban15$9,853
Cefpodoxime Proxetil20$528
Nitroglycerin14$356
ClopidogrelClopidogrel Bisulfate17$168
Metoprolol Succinate28$164
Pantoprazole Sodium18$114
Prednisone25$87
Atorvastatin Calcium15$86
Furosemide21$75
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$64
Metoprolol Tartrate12$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$385$10,70222 claims
PfizerEliquis$110$9,85315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 349 hospitalist providers in Connecticut.

Other hospitalist in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →